On 1st November, 2017, the U.S. Environmental Protection Agency (EPA) announced that they had reached an agreement with a pharmaceutical company in New Jersey to resolve allegations that the company had violated the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) by selling and distributing unregistered and misbranded antimicrobial pesticides.
The pesticides were used in the healthcare sector to clean ultrasound and mammography equipment, before the pharmaceutical company voluntarily recalled both products. They claimed that the products would kill microorganisms, however, this claim was not substantiated by the EPA registration process and so the products were not demonstrated to the EPA to ensure they did not pose potential health risks.
The pharmaceutical company paid a civil penalty of $250,000 in settlement of the case and have confirmed that they have now compiled with FIFRA. The aim of the settlement was to safeguard against sellers and distributors marketing their product without first registering with the EPA, and to also ensure that antimicrobial products are not mislabelled.
To find out more about this, please visit the EPA website.